UPDATE: Goldman Sachs Assumes Kiniksa (KNSA), Upgrades to Buy on Attractive Risk/Reward Offering

December 6, 2019 4:39 AM EST
Get Alerts KNSA Hot Sheet
Price: $12.19 +2.09%

Rating Summary:
    6 Buy, 0 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 7 | Down: 15 | New: 24
Trade Now! 
Join SI Premium – FREE
(Updated - December 6, 2019 5:25 AM EST)

Goldman Sachs analyst Paul Choi assumes primary coverage on Kiniksa (NASDAQ: KNSA) with a Buy rating (from Neutral) and a price target of $18.00.

The analyst comments "We upgrade KNSA to Buy from Neutral as we think the current valuation offers an attractive risk/reward potential ahead of multiple clinical catalysts in 2020 that could drive a meaningful reappraisal of the stock. Our KOL checks suggest increasing receptivity towards using biologics to treat GCA, with mavrilimumab seen as potentially differentiated on both efficacy and safety relative to Actemra. While it represents a smaller opportunity, rilonacept (Arcalyst) for recurrent pericarditis is already partially de-risked, with clinical success shifting more of the asset’s economics into KNSA’s control."

For an analyst ratings summary and ratings history on Kiniksa click here. For more ratings news on Kiniksa click here.

Shares of Kiniksa closed at $9.97 yesterday.

You May Also Be Interested In

Related Categories

Analyst Comments, Hot Comments, Hot New Coverage, Hot Upgrades, New Coverage, Upgrades

Related Entities

Goldman Sachs